As SARS-CoV-2 has evolved and mutated, therapeutic antibodies that worked early in the pandemic have become less effective, and newer variants, especially omicron, have developed ways to evade the antibodies we make in response ...
Aug 11, 2022
0
170
Since June, the number of COVID-19 infections started rising again, as the most transmissible omicron variant started picking up delta variant mutations leading to new subvariants BA.4/BA.5 and Deltacron variants. Out of ...
Jul 15, 2022
0
91
The omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. In many countries, these viruses are now outcompeted by emerging subvariants, with BA.5 being responsible for the current ...
Jul 1, 2022
0
149
They say that the best defense is a good offense; and now, researchers from Japan have found that the best defense against coronavirus disease 2019 (COVID-19) infection could be a good decoy.
Apr 27, 2022
0
63
Researchers from North Carolina State University have discovered that a particular molecular signaling pathway plays an important role in producing osteoarthritis (OA) pain. Using a mouse model of painful osteoarthritis, ...
Jan 27, 2022
0
107
The omicron variant of SARS-CoV-2 is spreading at an alarming rate. It could soon replace the delta variant, which at present dominates globally. However, little is known about whether currently available vaccines and drugs ...
Dec 29, 2021
2
931
A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, adds more evidence that the omicron variant can evade the immune protection conferred by vaccines and natural infection ...
Dec 17, 2021
0
68
The emergence of new SARS-CoV-2 variants that can spread rapidly and undermine vaccine-induced immunity threatens the end of the COVID-19 pandemic. The delta variant (B.1.617.2) emerged in India and subsequently spread globally ...
Oct 18, 2021
0
59
A study led by Nicolas Bazan, MD, Ph.D., Boyd Professor and Director of LSU Health New Orleans Neuroscience Center of Excellence, reports that in an experimental model of glioblastoma multiforme (GBM), a combination of approved ...
Sep 30, 2021
0
19
The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by researchers at the University of Minnesota Medical School.
Sep 7, 2021
0
15
